

BIOINFORMANT

Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report



1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY

TABLE OF CONTENTS

1.	REPORT OVERVIEW	17
1.1	Statement of the Report	17
1.2	Executive Summary	19
2.	INTRODUCTION	21
3.	CURRENT STATUS OF iPSC INDUSTRY	22
3.1	Progress Made in Autologous Cell Therapy using iPSCs	22
3.1.1	Examples of Autologous iPSC-derived Cell Therapies in Development	23
3.2	Manufacturing Timeline for Autologous iPSC-Derived Cell Products	24
3.3	Cost of iPSC Production	25
3.4	Automation in iPSC Production	26
3.5	Allogeneic iPSCs Gaining Momentum	27
3.5.1	Ongoing Clinical Trials involving Allogeneic iPSCs	28
3.6	Share of iPSC-based Research within the Overall Stem Cell Industry	28
3.7	Major Focus Areas of iPSC Companies	29
3.8	Commercially Available iPSC-derived Cell Types	30
3.9	Relative use of iPSC-derived Cell Types in Toxicology Testing Assays	31
3.10	Currently Available iPSC Technologies	32
3.10.1	Brief Descriptions of some Recently introduced iPSC-related Technologies	34
3.10.1.1	Nucleofactor Technology	34
3.10.1.2	opti-ox Technology	35
3.10.1.3	MOGRIFY Technology	35
3.10.1.4	Transcription Factor-Based iPSC Differentiation Technology	36
3.10.1.5	Flowfect Technology	36
3.10.1.6	Technology for Mass Production of Platelets from Megakaryocytes	36
3.10.1.7	SynFire Technology	38
4.	HISTORY OF INDUCED PLURIPOTENT STEM CELLS (iPSCS)	39
4.1	First iPSC Generation from Mouse Fibroblasts, 2006	40
4.2	First Human iPSC Generation, 2007	40
4.3	Creation of CiRA, 2010	40
4.4	First High-Throughput Screening using iPSCs, 2012	40
4.5	First iPSC Clinical Trial Approved in Japan, 2013	41
4.6	First iPSC-RPE Cell Sheet Transplantation for AMD, 2014	41
4.7	EBiSC Founded, 2014	41
4.8	First Clinical Trial using Allogeneic iPSCs for AMD, 2017	41
4.9	Clinical Trial for Parkinson's disease using Allogeneic iPSCs, 2018	42
4.10	Commercial iPSC Plant SMaRT Established, 2018	42
4.11	First iPSC Therapy Center in Japan, 2019	42
4.12	First U.S. Based NIH-Sponsored Clinical Trial using iPSCs, 2019	42
4.13	Cynata Therapeutics' World's Largest Phase III Clinical Trial, 2020	43
4.14	Tools and Know-how to Manufacture iPSCs in Clinical Trials, 2021	43
4.15	Production of In-House iPSCs using Peripheral Blood Cells, 2022	43
5.	RESEARCH PUBLICATIONS ON iPSCS	44
5.1	The Fast Growth in iPSC Publications	44
5.1.1	PubMed Publications on Pathophysiological Research	46
5.1.2	PubMed Papers in Reprogramming	46

5.1.3	PubMed Papers in iPSC Differentiation	47
5.1.4	PubMed Papers on the use of iPSCs in Drug Discovery	48
5.1.5	PubMed Papers on iPSC-based Cell Therapy	49
5.2	Percent Share of Published Articles by Disease Type	50
5.3	Percent Share of Articles by Country	51
6.	iPSC: PATENT LANDSCAPE ANALYSIS	53
6.1	Legal Status of iPSC Patents	53
6.2	Patents by Assignee Organization Type	54
6.3	Ownership of Patent Families by Assignee Type	54
6.4	Top Inventors of iPSC Patents	55
6.5	Top Ten iPSC Inventors	56
6.6	Most Cited Five iPSC Patents	57
6.7	Leading Patent Filing Jurisdictions	58
6.8	Number of Patent Families by Year of Filing	59
6.9	Patents Representing Different Disorders	60
6.10	iPSC Patents on Preparation Technologies	60
6.11	Patents on Cell Types Differentiated from iPSCs	62
6.12	Patent Application Trends Disease-Specific Technologies	63
7.	iPSC: CLINICAL TRIAL LANDSCAPE	65
7.1	Literature and Database Search	65
7.2	Number of iPSC Clinical Trials by Year	65
7.3	iPSC Study Designs	66
7.3.1	Therapeutic and Non-Therapeutic Studies	67
7.3.2	Non-Therapeutic Clinical Trials by Use	68
7.3.2.1	Top Ten Countries with the Ongoing Non-Therapeutic Studies	68
7.3.2.2	Diseases Targeted by Non-Therapeutic Studies	69
7.3.3	Therapeutic Studies	70
7.3.3.1	Therapeutic Studies by Phase of Study	71
7.3.3.2	Therapeutic Studies by Disease Type	71
7.3.3.3	Examples of Therapeutic Interventional Studies	72
7.3.3.4	Future Outlook for Therapeutic Clinical Trials using iPSCs	74
7.4	iPSC-Based Clinical Trials with Commercialization Potential	75
8.	RESEARCH FUNDING FOR iPSCS	77
8.1	Value of NIH Funding for iPSC Research	78
8.2	Partial List of NIH Funded iPSC Research Projects in 2022	79
9.	M&A, COLLABORATIONS & FUNDING ACTIVITIES IN iPSC SECTOR	80
9.1	Mergers and Acquisitions (M&A) in iPSC Sector	80
9.1.1	Evotec & Rigenerand	80
9.1.2	Catalent & RheinCell Therapeutics	81
9.1.3	Axol Bioscience & Censo Biotechnologies	81
9.1.4	Bayer AG & BlueRock	81
9.1.5	Pluriomics & Axiogenesis	81
9.2	Partnership/Collaboration/Licensing Deals in iPSC Sector	82
9.2.1	Evotec & Sernova	83
9.2.2	Evotec SE & Almirall, SA	84
9.2.3	Quell Therapeutics & Cellistic	84
9.2.3.1	Terms of the Collaboration	84

9.2.4	MDimmune & YiPSCELL	85	
9.2.5	EdiGene & Neukio Biotherapeutics	85	
9.2.6	Matricelf & Ramot	85	
9.2.7	Evotec & Boehringer Ingelheim	85	
9.2.8	Plurityx, Pancella & Implant Therapeutics	86	
9.2.9	Century Therapeutics & Bristol Myers Squibb	86	
9.2.10	Terms of the Collaboration	86	
9.2.11	Fujifilm Cellular Dynamics & Pheno Vista Biosciences	87	
9.2.12	Metrion Biosciences & Bioqube Ventures	87	
9.2.13	Cytovia Therapeutics & Collectis	87	
9.2.14	Exacis Biotherapeutics & CCRM	88	
9.2.15	Cynata Therapeutics & Fujifilm Corporation	88	
9.2.16	Bone Therapeutics & Implant Therapeutics	88	
9.2.17	REPROCELL & TEXCELL	89	
9.2.18	Jacobio & Herbecell	89	
9.2.19	NeuCyte & KIF1A.ORG	89	
9.2.20	Kite & Shoreline Biosciences	90	
9.2.21	Neurophth Therapeutics & Hopstem Biotechnology	90	
9.2.22	Allele Biotech & Cellatoz	91	
9.2.23	BlueRock Therapeutics, Fujifilm Cellular Dynamics & Opsi Therapeutics	91	
9.2.24	Newcells & Takeda	92	
9.2.25	Biocentriq & Kytopen	92	
9.2.26	Fujifilm Cellular Dynamics & Sana Biotechnology	92	
9.2.27	Evotec & Medical Center Hamburg-Eppendorf (UKE)	92	
9.2.28	NeuCyte & Seaver Autism Center for Research and Treatment	93	
9.2.29	Cytovia Therapeutics & National Cancer Institute	93	
9.2.30	Mogrify & MRC Laboratory of Molecular Biology	93	
9.3	Venture Capital Funding and IPOs	94	
9.3.1	Aspen Neuroscience	95	
9.3.2	Axol Biosciences Ltd.	95	
9.3.3	Thyas Co. Ltd.	96	
9.3.4	Synthego	96	
9.3.5	Cellino Biotech, Inc.	97	
9.3.6	Curi Bio	97	
9.3.7	Ncardia	97	
9.3.8	Evotec SE	98	
9.3.9	bit.bio	98	
9.3.10	Clade Therapeutics	98	
9.3.11	Shoreline Biosciences	98	
9.3.12	Kytopen	99	
9.3.13	Cytovia Therapeutics & CytoLynx	99	
9.3.14	TreeFrog Therapeutics	100	
9.3.15	HebeCell Corporation	100	
9.3.16	Neukio Biotherapeutics	100	
9.3.17	Stemson Therapeutics	101	
9.3.18	Vita Therapeutics	101	
9.3.19	Century Therapeutics	102	
9.3.20	Heartseed	102	
9.3.21	Mogrify	102	
9.3.22	Metrion Biosciences	103	
9.3.23	Axol Biosciences	103	
9.3.24	Axol Bioscience	103	
9.3.25	Elevate Bio	104	
9.3.26	Vita Therapeutics	104	

10.	GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW	105
10.1	Reprogramming Factors	106
10.1.1	Pluripotency-Associated Transcription Factors and their Functions	107
10.1.2	Different Combinations of Factors for Different Cell Sources	109
10.1.3	Delivery of Reprogramming Factors	109
10.2	Integrating iPSC Delivery Methods	110
10.2.1	Retroviral Vectors	111
10.2.2	Lentiviral Vectors	111
10.2.3	piggyBac (PB) Transposon	112
10.3	Non-Integrative Delivery Systems	113
10.3.1	Adenoviral Vectors	113
10.3.2	Sendai Viral Vectors	114
10.3.3	Plasmid Vectors	114
10.3.4	Minicircles	114
10.3.5	oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes	114
10.3.6	RNA	115
10.3.7	Proteins	116
10.4	Comparison of Delivery Methods for generating iPSCs	116
10.5	Genome Editing Technologies in iPSC Generation	118
10.5.1	CRISPR/Cas9	118
11.	HUMAN iPSC BANKING	121
11.1	Cell Sources for iPSC Banking	122
11.2	Reprogramming Methods used in iPSC Banking	122
11.3	Factors used in Reprogramming in Different Banks	122
11.4	Workflow in iPSC Banks	123
11.5	Existing iPSC Banks	124
11.5.1	California Institute for Regenerative Medicine (CIRM)	124
11.5.1.1	CIRM iPSC Repository	125
11.5.1.2	Key Partnerships Supporting CIRM's iPSC Repository	126
11.6	Regenerative Medicine Program (RMP)	126
11.6.1	Research Grade iPSC Lines for Orphan & Rare Diseases with RMP	127
11.6.2	RMP's Stem Cell Translation Laboratory (SCTL)	129
11.7	Center for iPSC Cell Research and Application (CiRA)	129
11.8	FiT – Facility for iPS Cell Therapy	130
11.9	European Bank for Induced Pluripotent Stem Cells (EBiSC)	130
11.10	Korean Society for Cell Biology (KSCB)	131
11.11	Human Induced Pluripotent Stem Cell Initiative (HipSci)	131
11.12	RIKEN – BioResource Research Center (BRC)	131
11.13	Taiwan Human Disease iPSC Consortium	133
11.14	WiCell	134
12.	BIOMEDICAL APPLICATIONS OF iPSCS	135
12.1	iPSCs in Basic Research	136
12.1.1	To Understand Cell Fate Control	136
12.1.2	To Understand Cell Rejuvenation	136
12.1.3	To Understand Pluripotency	136
12.1.4	To Study Tissue & Organ Development	137
12.1.5	To Produce Human Gametes from iPSCs	137
12.1.6	Providers of iPSC-Related Services for Researchers	137

12.2	iPSCs in Drug Discovery	139	
12.2.1	Advantages	139	
12.2.2	Drug Discovery for Cardiovascular Diseases using iPSCs	140	
12.2.3	Drug Discovery for Neurological Diseases using iPSCs	142	
12.2.4	Drug Discovery for Rare Diseases using iPSCs	144	
12.3	iPSCs in Toxicology Studies	146	
12.3.1	Testing Drugs for DILI	147	
12.3.2	Examples of Drugs Tested in iPSC-derived Cells	147	
12.3.3	Relative use of iPSC-derived Cell Types in Toxicity Testing Studies	149	
12.4	iPSCs in Disease Modeling	150	
12.4.1	Cardiovascular Diseases Modeled with iPSC-derived Cells	155	
12.4.1.1	Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling	156	
12.4.2	Modeling Liver Diseases using iPSC-derived Hepatocytes	157	
12.4.3	iPSCs in Neurodegenerative Disease Modeling	159	
12.4.4	iPSC-derived Organoids for Modeling and Diseases	164	
12.4.5	Cancer-Derived iPSCs	165	
12.5	iPSCs in Cell-Based Therapies	166	
12.5.1	Companies Focusing only on iPSC-based Cell Therapy	167	
12.6	Other Novel Applications of iPSCs	167	
12.6.1	iPSCs in Tissue Engineering	168	
12.6.1.1	3D Bioprinting Techniques	168	
12.6.1.2	Biomaterials	168	
12.6.1.3	3D Bioprinting Strategies	168	
12.6.1.4	Bioprinting iPSC-derived Cells	171	
12.6.2	iPSCs from Farm Animals	172	
12.6.2.1	Porcine iPSCs	172	
12.6.2.2	Bovine iPSCs	172	
12.6.2.3	Ovine and Caprine iPSCs	172	
12.6.2.4	Equine iPSCs	173	
12.6.2.5	Avian iPSCs	173	
12.7	iPSCs in Animal Conservation	173	
12.7.1	iPSC Lines for the Preservation of Endangered Species of Animals	173	
12.7.2	iPSCs in Wildlife Conservation	175	
12.7.3	iPSCs in Cultured Meat	176	
13.	MARKET OVERVIEW	178	
13.1	Global Market for iPSCs by Geography	180	
13.2	Global Market for iPSCs by Technology	181	
13.3	Global Market for iPSCs by Biomedical Application	183	
13.4	Global Market for iPSCs by Derived Cell Type	185	
13.5	Market Drivers	187	
13.5.1	Current Drivers Impacting the iPSC marketplace	187	
13.6	Market Restraints	188	
13.6.1	Economic Issues	188	
13.6.2	Genomic Instability	188	
13.6.3	Immunogenicity	188	
13.6.4	Biobanking	189	

14.	COMPANY PROFILES	190	
14.1	Accellta	190	
14.1.1	Technology	190	
14.1.2	Maxells	190	
14.1.3	Singles	191	
14.1.4	Diffentiation	191	
14.1.5	Services	191	
14.2	AddGene, Inc.	192	
14.2.1	Viral Plasmids	192	
14.3	Allele Biotechnology, Inc.	193	
14.3.1	iPSC Reprogramming and Differentiation	193	193
14.3.2	cGMP Facility	193	
14.4	ALSTEM, Inc.	194	
14.4.1	Services	194	
14.4.2	iPSC-related Products	194	
14.4.3	Human iPS Cell Lines	195	
14.4.4	Inducible iPS Cell Lines	195	
14.4.5	Isogenic iPS Cell Lines	195	
14.4.6	Knockout Cell Lines	196	
14.5	Altos Labs	196	
14.6	AMS Biotechnology Ltd. (AMSBIO)	197	
14.6.1	iPSC-derived Cells and Differentiation Kits	197	197
14.6.2	iPSC-derived Excitatory Neurons	197	
14.6.3	iPSC-derived Dopaminergic Neurons	198	
14.6.4	iPSC-derived GABAergic Neurons	198	
14.6.5	iPSC-derived Cholinergic Neurons	198	
14.6.6	iPSC-derived Skeletal Muscle	198	
14.7	Aspen Neuroscience, Inc.	199	
14.7.1	Aspen's Clinical Pipeline	199	
14.8	Astellas Pharma, Inc.	200	
14.8.1	Leading Program	200	
14.9	Avery Therapeutics	201	
14.9.1	MyCrdia	201	
14.10	Axol Bioscience Ltd.	202	
14.10.1	iPSC-derived Cells	202	
14.10.2	Disease Models	202	
14.10.3	Services	203	
14.10.4	Custom Cell Services	203	
14.10.5	Stem Cell Reprogramming	203	
14.10.6	Genome Editing	203	
14.10.7	Stem Cell Differentiation	204	
14.11	Bit.bio	205	
14.11.1	Opti-OX Reprogramming Technology	205	
14.11.2	ioCells	205	
14.11.3	ioWild Type Cells	206	
14.11.4	ioGlutamatergic Neurons	206	
14.11.5	ioSkeletal Myocytes	206	
14.11.6	ioGABAergic Neurons	206	
14.11.7	ioDisease Models	207	
14.11.8	ioGlutamatergic Neurons HTT50CAGWT	207	207
14.12	BlueRock Therapeutics	208	
14.12.1	CELL + GENE Platform	208	208
14.13	BrainXell	209	
14.13.1	Products	209	
14.13.1.1	Spinal Motor Neurons	209	

14.13.1.2	Midbrain Dopaminergic Neurons	210
14.13.1.3	Cortical Glutamatergic Neurons	210
14.13.1.4	Mixed Cortical Neurons	210
14.13.1.5	Cortical Astrocytes	210
14.13.1.6	Layer V Glutamatergic Neurons	210
14.13.1.7	Cortical GABAergic Neurons	211
14.13.1.8	Microglia	211
14.13.1.9	Medium Spiny Neurons	211
14.13.1.10	Spinal Astrocytes	211
14.14	Brooklyn Immuno Therapeutics	212
14.14.1	Synthetic mRNA	212
14.14.2	Non-Viral Nucleic Acid Delivery	212
14.14.3	Cellular Reprogramming	213
14.14.4	Gene Editing	213
14.15	Catalent Biologics	214
14.15.1	Human iPSCs	214
14.16	Celogics, Inc.	215
14.16.1	Celo.Cardiomyocytes	215
14.17	Cellaria	215
14.17.1	Lung Cancer Cell Models	216
14.17.2	Breast Cancer Cell Models	216
14.17.3	Colon Cancer Cell Lines	216
14.17.4	Ovarian Cancer Cell Lines	216
14.17.5	Pancreatic Cancer Cell Lines	216
14.17.6	Cancer Research Custom Services	217
14.17.7	Stem Cell Services	217
14.18	CellGenix, GmbH	218
14.18.1	Products	218
14.19	Cellino Biotech	219
14.19.1	Cellino's Technology Platform	219
14.20	Cellular Engineering Technologies (CET)	220
14.20.1	Products	220
14.20.2	iPS Cell Lines	220
14.20.3	Drug Discovery Services	221
14.20.4	iPSC Reprogramming Services	221
14.21	Geno Biotechnologies, Ltd.	222
14.21.1	Neuroinflammation	222
14.21.2	Inflammation	222
14.21.3	Neurobiology	223
14.22	Century Therapeutics, Inc.	223
14.22.1	Cell Therapy Platform	223
14.22.2	Century's Pipeline	224
14.23	Citius Pharmaceuticals, Inc.	225
14.23.1	Stem Cell Platform of iMSCs	225
14.24	Clade Therapeutics	226
14.25	Creative Bioarray	226
14.25.1	iPSC Reprogramming Kits	226
14.25.2	QualiStem Episomal iPSC Reprogramming Kit	227
14.25.3	QualiStem RNA iPSC Reprogramming Kit	227
14.25.4	QualiStem Retrovirus iPSC Reprogramming Kit	227
14.25.5	QualiStem Lentivirus iPSC Reprogramming Kit	228
14.25.6	QualiStem iPSC Protein Reprogramming Kit	228
14.25.7	iPSC Characterization Kits	228
14.25.8	Alkaline Phosphatase Staining Assay	228
14.25.9	Pluripotency Markers (Protein)	228
14.25.10	Pluripotency Markers (mRNA)	229

14.25.11	iPSC Differentiation Kits	229	
14.25.12	QualiStem iPSC Cell Cardiomyocyte Differentiation Kit	229	
14.25.13	QualiStem Human iPSC Cell Dopaminergic Neuron Differentiation Kit	229	229
14.25.14	QualiStem iPSC Cell Neural Progenitor Differentiation Kit	229	
14.25.15	QualiStem iPSC Cell Endoderm Differentiation Kit	230	
14.25.16	QualiStem iPSC Cell Ectoderm Differentiation Kit	230	
14.25.17	QualiStem iPSC Cell Mesoderm Differentiation Kit	230	
14.25.18	QualiStem iPSC Cell Hepatocyte Differentiation Kit	230	230
14.25.19	iPSC Myogenic Progenitor Differentiation kit	231	
14.26	Curi Bio	231	
14.26.1	Disease Model Development	231	
14.26.2	Assay Development	232	
14.26.3	Discovery	232	
14.26.4	Cell Repositories	232	
14.27	Cynata Therapeutics Ltd.	233	
14.27.1	Cymerus Platform	233	
14.27.2	Clinical Development	233	
14.27.2.1	Graft vs. Host Disease	233	
14.27.2.2	Critical Limb Ischemia	234	
14.27.2.3	Osteoarthritis	234	
14.27.2.4	Acute Respiratory Syndrome	234	234
14.27.2.5	Diabetic Wounds	235	
14.27.2.6	Preclinical Development	235	
14.27.2.7	Idiopathic Pulmonary Fibrosis	235	235
14.27.2.8	Renal Transplantation	235	
14.27.2.9	Asthma	235	
14.27.2.10	Heart Attack	236	
14.27.2.11	Coronary Artery Disease	236	236
14.28	Cytovia Therapeutics	237	
14.28.1	Technology	237	
14.28.2	iNK & CAR-iNK Cells	237	
14.28.3	Flex-NK Cell Engagers	238	
14.29	DefiniGEN	239	
14.29.1	OptiDIFF iPSC Platform	239	239
14.29.2	Services	239	
14.29.2.1	Phenotypic Screening Services	239	
14.29.2.2	iPSC Differentiation Services	240	
14.29.2.3	Disease Modeling Services	240	
14.29.3	Products	240	
14.29.3.1	Hepatocyte WT	240	
14.29.3.2	NAFLD iPSC-Derived Hepatocytes	241	241
14.29.3.3	GSD1a Disease Modeled Hepatocytes	241	241
14.29.3.4	A1ATD Disease Modeled Hepatocytes	241	241
14.29.3.5	Hepatocyte Familial Hypercholesterolemia (FH)	241	241
14.29.3.6	Custom Model Development	242	
14.29.3.7	NAFLD PNPLA3	242	
14.29.3.8	NAFLD TM6SF2 Disease Modeled Hepatocytes	242	242
14.29.3.9	Intestinal Organoids	242	
14.29.3.10	Intestinal Monolayer	243	
14.29.3.11	Pancreatic Beta Cells (WT)	243	243
14.29.3.12	MODY3 Diabetes	243	
14.29.3.13	Neonatal Diabetes Pancreatic Cells	243	243
14.30	Editas Medicine	244	
14.30.1	iPSC-Derived NK Cells	244	
14.31	ElevateBio	245	
14.31.1	Technologies	245	

14.32	Elixirgen Scientific, Inc.	246	
14.32.1	Technology	246	
14.32.2	Services	246	
14.32.3	iPSC Products	247	
14.32.4	Reagents	248	
14.33	Evia Bio	248	
14.33.1	iPSCs Cryopreservation Solutions	248	
14.34	Evotec A.G.	249	
14.34.1	iPSCs Platform	249	
14.34.2	Drug Discoveries	250	
14.35	Exacis Biotherapeutics	251	
14.35.1	ExaCELLs	251	
14.36	Eyestem	252	
14.36.1	Eyecyte-RPE	252	
14.37	Fate Therapeutics	253	
14.37.1	iPSCs Platform	253	
14.37.2	Pipeline	254	
14.37.3	Collaborations	254	
14.37.3.1	Janssen Biotech	254	
14.37.3.2	ONO Pharmaceutical	255	
14.38	FUJIFILM Cellular Dynamics, Inc. (FCDI)	255	
14.38.1	Products	255	
14.38.2	MyCell Custom Services	257	
14.38.3	Disease Modeling Applications	257	
14.38.4	Drug Discovery Applications	258	
14.38.5	Applications in Toxicity Testing	259	
14.39	Heartseed, Inc.	260	
14.39.1	Technology	260	
14.40	HebeCell	261	
14.40.1	Technology	261	
14.41	Helios K.K.	262	
14.42	Hera BioLabs	263	
14.42.1	Services	263	
14.42.2	Products	263	
14.42.3	piggyBac Transposase/Transposon	263	
14.43	Hopstem Biotechnology	264	
14.43.1	Research & Development	264	
14.43.2	Product Pipeline	265	
14.44	Implant Therapeutics, Inc.	266	
14.44.1	Services	266	
14.45	iPS Portal, Inc	267	
14.45.1	Services	267	
14.45.1.1	Research Support and Contract Testing Services	267	
14.45.1.2	Development Support Services	268	
14.45.2	Business Support	268	
14.46	I Peace, Inc.	269	
14.46.1	Mass Production of iPSCs	269	
14.47	iXCells Biotechnologies	270	
14.47.1	Products	270	
14.47.2	Services	271	
14.47.3	iPS Cell Generation	271	
14.47.4	Genome Editing	271	
14.47.5	iPSC Differentiation	272	
14.48	Kytopen	273	
14.48.1	Flowfect Technology	273	
14.49	LizarBio Therapeutics	274	

14.49.1	Pipeline	274	
14.50	Lonza Group, Ltd.	275	
14.50.1	iPSC Manufacturing Expertise	275	
14.50.2	Nucleofector Technology	275	
14.51	Matricelf	276	
14.52	Merck/Sigma Aldrich	277	
14.52.2	Merck's iPSC Products and Services	277	
14.53	Megakaryon Corporation	278	
14.53.1	Technology	278	
14.53.2	Research and Development Pipeline	279	
14.53.3	Cryopreservable Megakaryon Strain	280	
14.53.4	Treatable Diseases by Products from Megakaryon	280	
14.54	Metrion Biosciences, Ltd.	281	
14.54.1	Cardiac Safety Screening Services	281	
14.54.2	Neuroscience Assay Services	281	
14.54.3	Cardiac Assay Services	282	
14.54.4	Neuroscience Translational Assay Services	282	
14.54.5	Integrated Drug Discovery Service	282	
14.55	Mogrify	283	
14.55.1	Mogrify Platform	283	
14.55.2	epiMogrify Platform	284	
14.56	Ncardia	285	
14.56.1	iPSC Platform	285	
14.56.2	Human iPSC-derived Cell Models	286	
14.56.3	Drug Discovery Solutions	286	
14.56.4	Developing iPSC-derived Cell Types	286	
14.56.5	Assay Development	287	
14.56.6	High-Throughput Screening	287	
14.57	NeuCyte	288	
14.57.1	SynFire Technology	288	
14.58	Neukio Biotherapeutics	289	
14.58.1	iPSC-CAR-NK	289	
14.59	Newcells Biotech, Ltd	290	
14.59.1	Retinal Platform	290	
14.59.2	Kidney Platform	290	
14.59.3	Lung Model	291	
14.60	NEXEL Co., Ltd.	291	
14.60.1	Cardiosight-S	291	
14.60.2	Hepatocyte-S	291	
14.60.3	Neurosight-S	292	
14.60.4	NeXST Cardiac Safety Service	292	
14.61	Orizuru Therapeutics, Inc.	293	
14.61.1	iCM Project	293	
14.61.2	iPIC Project	293	
14.62	Phenocell SAS	294	
14.62.1	Cells and Kits	294	
14.62.2	R&D Outsourcing Services	295	
14.63	Platelet BioGenesis	295	
14.63.1	Technology	295	
14.64	Pluristyx	296	
14.64.1	RTD and RTU Technologies	296	
14.64.2	Products	296	
14.64.3	Services	297	
14.65	ReNeuron	298	
14.65.1	Technology Platform	298	
14.66	REPROCELL USA, Inc.	299	

14.66.1	RNA Reprogramming Kit	299	
14.66.2	NutriStem Culture Medium for Human iPSCs and ES Cells	300	
14.66.3	Induced Pluripotent Stem Cells	300	
14.66.4	StemRNA Neuro	301	
14.66.5	iPSCs Master Cell Bank	301	
14.67	RxCell, Inc.	302	
14.67.1	Services	302	
14.68	SCG Cell Therapy Pte Ltd.	303	
14.68.1	Acquisition of Technology	303	
14.69	Shoreline Biosciences	304	
14.69.1	iNK Cell Platform	304	
14.69.2	iPSC-Derived iMACs	304	
14.70	Stemson Therapeutics	305	
14.70.1	Hair Follicle Biology	305	
14.71	Stemina Biomarker Discovery	306	
14.71.1	Cardio quickPredict	306	
14.71.2	devTOX quickPredict	307	
14.72	Synthego Corp.	307	
14.72.1	Knockout iPSCs	307	
14.72.2	Knock-in iPSCs	308	
14.73	Tempo Bioscience	308	
14.73.1	Human iPSC-derived Sensory Neurons	308	
14.73.2	Human iPSC-derived Schwann Cells	309	
14.73.3	Human iPSC-derived Phagocytes	309	
14.73.4	Human iPSC-derived CD14+ Monocytes	309	
14.73.5	Human iPSC-derived Cardiomyocytes	309	
14.73.6	hiPSC-derived Kidney Proximal Tubules and Podocyte 3D Spheroids	310	
14.73.7	Human iPSC-derived Osteoblasts	310	
14.73.8	Human iPSC-derived MSCs	310	
14.73.9	Human iPSC-derived Retinal Pigment Epithelials	310	
14.73.10	Human iPSC-derived Motor Neurons	311	
14.73.11	Human iPSC-derived Microglia	311	
14.73.12	Human iPSC-derived Keratinocytes	311	
14.73.13	Human iPSC-derived Melanocytes	311	
14.73.14	Human iPSC-derived Dopaminergic Neurons	312	
14.73.15	Human iPSC-derived Cortical Neurons	312	
14.73.16	Human iPSC-derived Oligodendrocyte Progenitor Cells (OPCs)	312	
14.73.17	Human iPSC-derived Astrocytes	312	
14.73.18	Human iPSC-derived Neural Progenitor Cells	313	
14.74	Thyas, Co., Ltd.	313	
14.74.1	iTCR-T (iPSC-derived TCR-T)	313	
14.74.2	iCAR-NK/ILC (iPSC-derived CAR-NK/ILC)	314	
14.74.3	Thya's Product Pipeline	314	
14.75	Universal Cells	315	
14.75.1	Technology	315	
14.75.2	Editing the Genome without Breaking It	316	
14.75.3	Cells for Every Organ	316	
14.76	ViaCyte, Inc.	317	
14.76.1	PEC-01 Cells	317	
14.76.2	Device Engineering	317	
14.77	Vita Therapeutics	318	
14.77.1	Technology	318	
14.77.2	VTA-100	318	
14.78	XCell Science, Inc.	319	
14.78.1	Cell Products	319	
14.78.2	Control Lines	320	

14.78.3	Services	320
14.79	Yashraj Biotechnology, Ltd.	321
14.79.1	iPSC and Differentiated Derivatives	321
14.79.1.1	iPSC-derived Human Cardiomyocytes	321
14.79.1.2	iPSC-derived Hepatocytes	322
14.79.1.3	iPSC-derived Astrocytes	322
14.79.1.4	iPSC-derived Forebrain Motor Neurons	322
14.79.1.5	iPSC-derived Endothelial Cells	322
14.79.1.6	iPSC-derived Midbrain Dopaminergic Neurons	322
14.80	YiPCELL	323
14.80.1	R&D Programs	323
14.80.2	MIUChon	323
14.80.3	MIUKin	323
14.80.4	MIURon	324

INDEX OF TABLES

TABLE 3.1:	Progression of Autologous iPSC-derived Cell Therapies toward the Clinic	23
TABLE 3.2:	Examples of Autologous iPSC-derived Cell Therapies in Development	23
TABLE 3.3:	Examples of Clinical Trials involving Allogeneic iPSCs	28
TABLE 3.4:	Currently Available iPSC Technologies	34
TABLE 4.1:	Timeline of Important Milestones Reached in iPSC Industry, 2006-2022	39
TABLE 5.1:	Number of Research Publications on iPSCs in PubMed.gov, 2006-May 2022	45
TABLE 6.1:	Top 20 Inventors of iPSC Patents by Legal Status	56
TABLE 6.2:	Top Ten iPSC Inventors	57
TABLE 6.3:	Most Cited Five iPSC Patents	57
TABLE 7.1:	Recruitment Status of iPSC Clinical Trials	65
TABLE 7.2:	Examples of Therapeutic Interventional Studies	72
TABLE 7.2:	(CONTINUED)	73
TABLE 7.2:	(CONTINUED)	74
TABLE 8.1:	A Partial List of Research Projects Supported by NIH, 2022	79
TABLE 9.1:	Mergers and Acquisitions (M&A) in iPSC Sector	80
TABLE 9.2:	Partnership/Collaboration Deals in iPSC Sector	82
TABLE 9.2:	(CONTINUED)	83
TABLE 9.3:	Venture Capital Funding and IPOs	94
TABLE 10.1:	Pluripotency-Associated Transcription Factors and their Functions	108
TABLE 10.2:	Different Combinations of Factors for Different Cell Sources	109
TABLE 10.3:	Comparison of Delivery Methods for in Producing iPSCs	117
TABLE 10.4:	iPSC Disease Models Generated by CRISPR/Cas9	119
TABLE 10.4:	(CONTINUED)	120
TABLE 11.1:	Cell Sources and Reprogramming Agents used in iPSC Banks	123
TABLE 11.2:	Diseased iPSC Lines Available in CIRM Repository	125
TABLE 11.3:	CIRM's iPSC Initiative Awards	126
TABLE 11.4:	Research Grade iPSCs Available with RMP	127
TABLE 11.5:	Research Grade iPSC Lines for Orphan & Rare Diseases with RMP	128
TABLE 11.6:	SCTL's Collaborations	129
TABLE 11.7:	A Partial List of iPSC Lines Available with EBiSC	130
TABLE 11.8:	List of Disease-Specific iPSCs Available with RIKEN	131
TABLE 11.8:	(CONTINUED)	132
TABLE 11.8:	(CONTINUED)	133
TABLE 11.10:	An Overview of iPSC Banks Worldwide	134
TABLE 12.1:	Providers of iPSC Lines & Parts Thereof for Research	138
TABLE 12.2:	Drug Discovery for Cardiovascular Diseases using iPSCs	140
TABLE 12.2:	(CONTINUED)	141

TABLE 12.2: (CONTINUED)	142	
TABLE 12.3: Drug Discovery for Neurological and Neuropsychiatric Diseases using iPSCs	143	
TABLE 12.3: (CONTINUED)	144	
TABLE 12.4: Drug Discovery for Rare Diseases using iPSCs	144	
TABLE 12.5: Examples of Drugs Tested in iPSC-derived Cells	148	
TABLE 12.5: (CONTINUED)	149	
TABLE 12.6: Published Human iPSC Models	151	
TABLE 12.6: (CONTINUED)	152	
TABLE 12.6: (CONTINUED)	153	
TABLE 12.6: (CONTINUED)	154	
TABLE 12.6: (CONTINUED)	155	
TABLE 12.7: Partial List of Cardiovascular & other Related Diseases Modeled using iPSCs		156
TABLE 12.8: Liver Diseases and Therapeutic Interventions Modeled using iPSCs	158	
TABLE 12.8: (CONTINUED)	159	
TABLE 12.9: Examples of iPSC-based Neurodegenerative Disease Modeling	160	
TABLE 12.9: (CONTINUED)	161	
TABLE 12.9: (CONTINUED)	162	
TABLE 12.9: (CONTINUED)	163	
TABLE 12.10: Organoid Types and Disease Modeling Applications	164	
TABLE 12.11: Examples of Cancer-derived iPSCs	165	
TABLE 12.12: Diseases Addressed by iPSC-derived Cells in Studies in Advanced Stages	166	
TABLE 12.13: Companies focusing exclusively on developing iPSC-based Therapies	167	
TABLE 12.14: Features of Different Bioprinting Techniques	170	
TABLE 12.15: Bioprinting of iPSC-derived Tissues	171	
TABLE 12.16: Achievements made using iPSCs for the Conservation of Animals	174	
TABLE 12.17: Two Companies using iPSCs for Cultured Meat Production	177	
TABLE 13.1: Estimated Global Market for iPSCs by Geography, 2021-2029	180	
TABLE 13.2: Estimated Global Market for iPSCs by Technology, 2021-2029	182	
TABLE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2021-2029	184	
TABLE 13.4: Global Market for iPSCs by Derived Cell Type, 2021-2029	186	
TABLE 14.1: Aspen's Clinical Pipeline	199	
TABLE 14.2: iPS Cell Lines from CET	221	
TABLE 14.3: Century Therapeutics' Pipeline Products	224	
TABLE 14.4: Cytovia's Product Pipeline	238	
TABLE 14.5: Fate Therapeutic's Product Pipeline	254	
TABLE 14.6: HebeCell's Product Pipeline	261	
TABLE 14.7: Healios' Research and Development Status	262	
TABLE 14.8: Hopstem's Product Pipeline	265	
TABLE 14.9: LizarBio's Pipeline Products	274	
TABLE 14.10: Megakaryon's Multiple Pipelines for iPS Platelet Products	279	
TABLE 14.11: StemRNA Human iPSCs from ReproCELL	300	
TABLE 14.12: Thya's Product Pipeline	315	

INDEX OF FIGURES

FIGURE 3.1: Manufacturing Timeline for Autologous iPSC-derived Cell Products	24
FIGURE 3.2: Manufacturing Cost for Manual and Automated Processes	25
FIGURE 3.3: Technical Set-up of the StemCellFactory (SCF)	26
FIGURE 3.4: Share of iPSC-based Research within the Overall Stem Cell Industry	29
FIGURE 3.5: Major Focuses of iPSC Companies	30
FIGURE 3.6: Commercially Available iPSC-derived Cell Types	31
FIGURE 3.7: Relative use of iPSC-derived Cell Types in Toxicology Testing Assays	32
FIGURE 3.8: Schematic Comparing Nucleofection and Lipofection	35
FIGURE 3.9: Schematic of Steps involved in Platelet Production	37

FIGURE 5.1: Number of Research Publications on iPSCs in PubMed.gov, 2006 - 2022	45
FIGURE 5.2: Number of Published Papers in Pathophysiological Research, 2006 - 2022	46
FIGURE 5.3: Number of PubMed Papers in Reprogramming, 2008 - 2022	47
FIGURE 5.4: Number of PubMed papers on iPSC Differentiation, 2006 - 2022	48
FIGURE 5.5: PubMed Papers on the use of iPSCs in Drug Discovery	49
FIGURE 5.6: PubMed Papers on the use of iPSCs in Cell Therapy	50
FIGURE 5.7: Percent Share of Published Articles by Disease Type	51
FIGURE 5.8: Percent Share of Articles by Country	52
FIGURE 6.1: Legal Status of iPSC Patents	53
FIGURE 6.2: Patents by Assignee Organization Type	54
FIGURE 6.3: Ownership of Patent Families by Assignee Type	55
FIGURE 6.4: Number of Patent Families by Top Ten Countries	58
FIGURE 6.5: Number of Patent Families Filed by Year. 2006-2020	59
FIGURE 6.6: Percent Share of Patents Representing Different Disorders	60
FIGURE 6.7: Percent Share of Patents on iPSC Preparation Methods	61
FIGURE 6.8: Percent Share of Patents Related to Cell Types Differentiated from iPSCs	63
FIGURE 6.9: Percent Share of Patent Applications for Disease-Specific Technologies	64
FIGURE 7.1: Number of iPSC Clinical Trials by Year, 2006-2022	66
FIGURE 7.2: Study Designs in iPSC Clinical Trials	67
FIGURE 7.3: Therapeutic and Non-Therapeutic Studies	67
FIGURE 7.4: Non-Therapeutic Clinical Trials by Use	68
FIGURE 7.5: Top Ten Countries with the Ongoing Non-Therapeutic Studies	69
FIGURE 7.6: Diseases Targeted by Non-Therapeutic Studies	70
FIGURE 7.7: Therapeutic Studies by Type of iPSCs Used	70
FIGURE 7.8: Therapeutic Studies by Phase of Study	71
FIGURE 7.9: Therapeutic Studies by Disease Type	72
FIGURE 8.1: Number of NIH Funding for iPSC Projects, 2010 - 2022	77
FIGURE 8.2: Value of NIH Funding for iPSC Research, 2010 - 2022	78
FIGURE 10.1: Overview of iPSC Technology	105
FIGURE 10.2: Generation of iPSCs from MEF Cultures using 24 Factors by Yamanaka	106
FIGURE 10.3: The Roles of OSKM Factors in the Induction of iPSCs	107
FIGURE 10.4: Schematic of Delivery Methods for iPSC Induction	110
FIGURE 10.5: Schematic of Retroviral Delivery Method	111
FIGURE 10.6: Schematic of Lentiviral Delivery	112
FIGURE 10.7: piggyBac (PB) Transposon Delivery	112
FIGURE 10.8: Adenoviral Vector Delivery	113
FIGURE 10.9: oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes	115
FIGURE 10.10: RNA Delivery	115
FIGURE 10.11: Protein Delivery	116
FIGURE 11.1: Workflow in iPSC Banks	124
FIGURE 12.1: Biomedical Applications of iPSCs: An Overview	135
FIGURE 12.2: Basic Cell Types Differentiated from iPSCs	139
FIGURE 12.3: Advantages of iPSCs in Drug Discovery	140
FIGURE 12.4: iPSCs and their Potential for Toxicity Testing and Drug Screening	146
FIGURE 12.5: Testing Drugs for Drug Induced Liver Injury using iPSCs	147
FIGURE 12.6: Relative use of iPSC-derived Cell Types in Toxicity Testing Studies	150
FIGURE 12.7: Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling	157
FIGURE 12.8: Schematic of Techniques used for iPSC Bioprinting	169
FIGURE 12.9: Schematic Showing the use of iPSCs in Protecting Endangered Species	175
FIGURE 12.10: General Workflow for Cultured Meat Production	176
FIGURE 13.1: Estimated Global Market for iPSCs by Geography through 2029	180
FIGURE 13.2: Estimated Global Market for iPSCs by Technology through 2029	182
FIGURE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2021-2029	185
FIGURE 13.4: Estimated Global Market for iPSCs by Derived Cell Type, 2022	186
FIGURE 14.1: Century's Approach in iPSC Therapy	224
FIGURE 14.2: Elixigen's iPSCs Differentiation	247

FIGURE 14.3: MyCell Custom Services	257
FIGURE 14.4: Hopstem's Research & Development	265
FIGURE 14.5: Kytopen's Push Button System	273
FIGURE 14.6: Manufacturing Flow of Products from Magakaryon	279
FIGURE 14.7: Treatable Diseases by Products from Megakaryon	280
FIGURE 14.8: Schematic of developing iPSC Neurons by SynFire Technology	288
FIGURE 14.9: Cardio quickPredict Process	306
FIGURE 14.10: Scematic of Thya's iTCR-T (iPSC-derived TCR-T)	314
FIGURE 14.11: Thya's iCAR-NK/ILC (iPSC-derived CAR-NK/ILC)	314



About BioInformant

BioInformant is the first and only market research firm to specialize in the stem cell industry.

BioInformant research has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, Goldman Sachs, and GE Healthcare, BioInformant is your global leader in stem cell industry data.

